Stocks of pharmaceutical companies are still thriving after the end of the pandemic

In the drug world, pharmaceutical company stocks did best during the COVID-19 pandemic, when they focused on developing the necessary vaccines to suppress the virus. They are now looking to expand their manufacturing footprint and are working on new drugs for serious diseases, whether diabetes or chronic kidney disease. In this analysis, we look at the plans of the leading pharmaceutical companies and their possible future outcomes.

Swiss pharmaceutical company Novartis has announced plans to acquire Seattle, US-based biotechnology firm Chinook Therapeutics in a $3.5 billion deal to expand its pipeline of advanced-stage drugs and a new type of treatment for the rare severe kidney disease IgAN using the drugs atrasentan and zigakibart. The acquisition process is expected to close in the second half of 2023, with shareholders receiving $3.2 billion, or $40 per share, and contingent value rights of up to $300 million. Stock reacted positively to the news, even hitting an all-time high last month. The company has seen its stock value increase more than 430 times since it went public in 1995. Current plans show a promising future for the company.

(1 EURO = 0.97 CHF)

Snímek obrazovky 2023-06-14 v 22.05.52

Novartis' stock performance over the past five years. (Source: Google) *

Novo Nordisk plans investment in Denmark

Danish pharmaceutical company Novo Nordisk has announced a significant investment of DKK 15.9 billion (USD 2.29 billion) to expand its Denmark plant. Demand for products used to treat serious chronic diseases is growing and the company plans to meet it with this investment in a plant focused on major biologically active pharmaceutical ingredients (APIs). The company has experienced supply constraints for semaglutide, which is used in the manufacture of popular diabetes drugs Ozempic and Wegovy, due to high demand. It will therefore reduce the supply of initial doses of Wegovy in the US in an effort to meet this demand. Construction of the new facility is already underway and production of the API ingredients is scheduled to begin in 2029, a process that is key to the company's continuous product development pipeline. The stock has seen nice steady growth in recent years, which the company presents as a stable investment opportunity. *

(EUR 1 = DKK 7.45)

Snímek obrazovky 2023-06-14 v 22.05.57

Novo Nordisk's stock performance over the past five years. (Source: Google) *

BioNTech in court over COVID-19 vaccines

The German pharmaceutical company BioNTech has been sued by a German woman, whose identity is protected by law, and who allegedly suffered side effects after being vaccinated with the COVID-19 vaccine. She is seeking at least EUR 150 thousand in damages from the company for physical harm relating to upper body swelling or sleep disturbance and unspecified material damage. German pharmaceutical law states that manufacturers are liable for damages only if medical science proves that their products cause disproportionate harm compared to their benefits. According to the company, the case is not substantiated and confirms the positive benefits of its vaccine, which it holds a marketing authorisation for the German market with Pfizer. The European Medicines Agency (EMA) has reaffirmed the safety of approved COVID-19 vaccines, including BioNTech's Comirnata. There are approximately 250 similar indictments in Germany.

Snímek obrazovky 2023-06-14 v 22.06.02

BioNTech's stock performance over the past five years. (Source: Google) *

Olivia Lacenova, principal analyst at Wonderinterest Trading Ltd.

* Past performance is no guarantee of future results

[1] Forward-looking statements are based on assumptions and current expectations, which may be inaccurate, or on the current economic environment, which may change. Such statements are not guarantees of future performance. They involve risks and other uncertainties that are difficult to predict. Results may differ materially from those expressed or implied by any forward-looking statements.

This text constitutes marketing communication. It is not any form of investment advice or investment research or an offer for any transactions in financial instrument. Its content does not take into consideration individual circumstances of the readers, their experience or financial situation. The past performance is not a guarantee or prediction of future results.

🍪 Cookies

We use cookies to store, access and process personal data to give you the best online experience. By clicking Accept Cookies you consent to storing all cookies and ensure best website performance. You can modify cookie preferences or withdraw consent by clicking Cookie Settings. To find out more about cookies and purposes, read our Cookie Policy and Privacy Notice.

Cookies settings


Cookie Control

What are cookies?

Cookies are small text files that enable us, and our service provides to uniquely identify your browser or device. Cookies normally work by assigning a unique number to your device and are stored on your browser by the websites that you visit as well as third-party service providers for those website. By the term cookies other technologies as SDKs, pixels and local storage are to be considered.


If Enabled

We may recognize you as a customer which enables customized services, content and advertising, services effectiveness and device recognition for enhanced security
We may improve your experience based on your previous session
We can keep track of your preferences and personalize services
We can improve the performance of Website.


If Disabled

We won't be able to remember your previous sessions, that won't allow us to tailor the website according to your preferences
Some features might not be available and user experience reduced without cookies


Strictly necessary means that essential functions of the Website can not be provided without using them. Because these cookies are essential for the properly working and secure of Website features and services, you cannot opt-out of using these technologies. You can still block them within your browser, but it might cause the disfunction of basic website features.

  • Setting privacy preferences
  • Secure log in
  • Secure connection during the usage of services
  • Filling forms

Analytics and performance tracking technologies to analyze how you use the Website.

  • Most viewed pages
  • Interaction with content
  • Error analysis
  • Testing and Measuring various design effectivity

The Website may use third-party advertising and marketing technologies.

  • Promote our services on other platforms and websites
  • Measure the effectiveness of our campaigns

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 92.59% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.